Esperion Therapeutics | ESPR - Passivo Circulante





Passivo Circulante Alterar Data
AbbVie USD 42.1B 1.19B 2026-03
Alnylam Pharmaceuticals USD 1.35B 116.87M 2026-03
Alterity Therapeutics Limited AUD 1.73M 2.77M 2025-12
Amarin USD 179.64M 14.82M 2026-03
Amgen USD 24.96B 534M 2026-03
Biogen USD 3B 350.5M 2026-03
BioMarin Pharmaceutical USD 793.15M 34.12M 2026-03
Cipla INR 70.14B 7.16B 2026-03
CSL USD 4.61B 207M 2025-12
Cytokinetics USD 199.18M 3.27M 2026-03
Daiichi Sankyo JPY 778.55B 77.51B 2025-12
Eli Lilly USD 36.63B 1.41B 2026-03
Esperion Therapeutics USD 300.36M 451K 2026-03
Geron USD 73.57M 40.25M 2026-03
Grifols EUR 2.37B 156.97M 2025-12
Halozyme Therapeutics USD 363.21M 186.12M 2026-03
Heron Therapeutics USD 90.52M 5.58M 2026-03
Ionis Pharmaceuticals USD 717M 66M 2026-03
Merck USD 26.94B 1.38B 2026-03
Minerva Neurosciences USD 2.29M 381K 2025-12
Moderna USD 2.4B 408M 2026-03
Nektar Therapeutics USD 53.54M 12.8M 2025-12
Pfizer USD 34.35B 2.64B 2026-03
PTC Therapeutics USD 923.6M 44.82M 2026-03
Puma Biotechnology USD 82.73M 3.63M 2025-09
Regeneron Pharmaceuticals USD 5.11B 739.3M 2026-03
Sanofi EUR 30.01B 1.66B 2026-03
Sarepta Therapeutics USD 499.16M 596.13M 2026-03
United Therapeutics USD 599.1M 38.5M 2026-03
Vanda Pharmaceuticals USD 145.16M 27.29M 2025-12